Production (Stage)
Cartesian Therapeutics, Inc.
RNAC
$10.32
-$0.10-0.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 244.93% | -296.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 244.93% | -296.12% | |||
| Cost of Revenue | 29.79% | -0.82% | |||
| Gross Profit | -12.51% | -9.55% | |||
| SG&A Expenses | 17.33% | 8.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.99% | 2.40% | |||
| Operating Income | -14.29% | -8.97% | |||
| Income Before Tax | -77.70% | 58.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -72.73% | 57.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -72.73% | 57.60% | |||
| EBIT | -14.29% | -8.97% | |||
| EBITDA | -11.07% | -7.96% | |||
| EPS Basic | -69.53% | 64.19% | |||
| Normalized Basic EPS | -1.92% | -61.69% | |||
| EPS Diluted | -64.55% | 63.11% | |||
| Normalized Diluted EPS | -1.92% | -61.69% | |||
| Average Basic Shares Outstanding | 1.89% | 18.40% | |||
| Average Diluted Shares Outstanding | 1.89% | 18.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||